Cognition Therapeutics, Inc
Cognition Therapeutics, Inc is a biopharmaceutical company based in Purchase, NY, specializing in the development of innovative therapies for neurodegenerative diseases. Their lead product candidate, CT1812, is an oral, small-molecule medication designed to rescue impaired cellular functions in the brain and eye, potentially slowing the progression of Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration.
With a focus on targeting the cellular damage response mechanism, Cognition Therapeutics aims to protect neurons and fight against neurodegenerative diseases. Their research and development efforts are centered around displacing toxic protein oligomers, maintaining the function of the sigma-2 receptor, and protecting retinal pigment epithelial cells. Through their innovative approach, Cognition Therapeutics strives to make a significant impact in the field of CNS disorders.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.